Sign In
Buy FBIO
$2.61
-0.0400 (-1.51%)
At Close: Jun 03, 2026
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
08:30am, Thursday, 05'th Oct 2023
Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
08:30am, Thursday, 07'th Sep 2023
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializi
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
08:30am, Thursday, 03'rd Aug 2023
MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializin
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
08:30am, Wednesday, 19'th Jul 2023
Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corpor
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
04:01pm, Friday, 19'th May 2023
Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
06:59pm, Monday, 15'th May 2023
Fortress Biotech (FBIO) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.18 per share a year ago.
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
09:00am, Wednesday, 22'nd Mar 2023
Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a
Fortress Biotech to Participate in Two March 2023 Investor Conferences
08:00am, Tuesday, 07'th Mar 2023
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializi
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
10:25pm, Monday, 14'th Nov 2022 Zacks Investment Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates
10:15pm, Monday, 14'th Nov 2022 Zacks Investment Research
Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains?
01:12pm, Monday, 14'th Nov 2022 Zacks Investment Research
Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript
10:42pm, Thursday, 10'th Nov 2022
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President and Chief Executive
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
10:35pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
09:01pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million
